Skeletal Muscle Relaxation For Endotracheal Intubation — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for skeletal muscle relaxation for endotracheal intubation. 1 active patents protecting 1 drugs from 1+ originators. First major cliff: 2039. Daily refresh.

1
Approved drugs
1
Active US patents
55/100
Avg vulnerability
—
Annual revenue covered

Originators in Skeletal Muscle Relaxation For Endotracheal Intubation

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Merck & Co. 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating skeletal muscle relaxation for endotracheal intubation. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Rocuronium
Rocuronium Bromide
 Merck & Co. 1 55 — 2039-07-22

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11998605 Rocuronium formulation 55 2039-07-22

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11998605 Rocuronium formulation 55 2039-07-22

Related